Novo secures European approval for oral Wegovy to extend lead over Lilly - Pharmaceutical Technology

Novo Nordisk is relying on first-mover advantage in the obesity pill arena to close the gap on Eli Lilly. Novo Nordisk is relying on first-mover advantage in the obesity pill arena to close the gap on Eli Lilly. Approval in Europe follows similar decisions in the US and UK, meaning Novo has won the race over rivals in all three territories. Credit: Below the Sky/Shutterstock.com. Novo Nordisk is continuing to maintain its advantage in the obesity pill race after winning European approval for oral Wegovy (semaglutide). The European Commission (EC) granted marketing authorisation to the oral glucagon-like peptide-1 receptor agonist…

Source: Pharmaceutical Technology